Nursing home staff and administrators are exhausted, overwhelmed, and ready for a break. Many have wondered if we will continue to see the devastation and tragedy of the early COVID-19 waves in nursing homes as each new variant emerges. A prospective cohort study published in The Lancet Healthy Longevity by Maria Krutikov and colleagues1 suggests that this might not be the case. The Article describes differences in hospital admissions and death during the delta versus omicron waves in nursing home residents enrolled in the VIVALDI cohort (ISRCTN 14447421) and suggests less risk of severe outcomes with the omicron variant. The study sample included a cohort of 2264 residents of skilled nursing facilities (median age 84·5 years, IQR 77·9–90·0) who were diagnosed with SARS-CoV-2 between Sept 1, 2021, and Feb 1, 2022, of whom 253 (11·2%) had a previous infection and 1468 (64·8%) had received a booster vaccination. The primary outcome was hospital admission within 14 days following a positive SARS-CoV-2 test, and the secondary outcome was mortality in the 28 days following a positive test. The authors found a 36% reduction in the adjusted risk of hospital admission (adjusted hazard ratio [aHR] 0·64, 95% CI 0·41–1·00; p=0·051) and a 32% reduction in the adjusted risk of mortality (aHR 0·68, 0·44–1·04; p=0·076) in the period when the omicron variant was dominant compared with the period before the emergence of omicron. The models assessed included age, sex, past infection, primary vaccination type, and time from booster vaccination. The analytic approach largely relied on the date of the first report of omicron in the UK (Dec 13, 2021), to distinguish between the omicron and delta predominant periods. A sub-analysis of 937 residents with confirmed variant identification based on S-gene and lineage data showed similar results to the entire cohort. Notably, the authors found a significant reduction in hospital admission and death in residents with previous infection or a booster dose received longer than a week before infection; however, outcomes were not significantly different in those who had received two doses of either the Pfizer or AstraZeneca vaccine (and who had not received a booster dose) compared with those who were unvaccinated. Although this was not a dedicated efficacy study, these outcomes allude to the importance of booster vaccinations, particularly in the vulnerable long-term care population. Although differences in vaccination coverage affected outcomes in the two waves, there were also changes in therapy for COVID-19 over the course of the study period, which is not thoroughly discussed in the manuscript. Between Sept 1, 2021, and Feb 1, 2022, monoclonal antibodies as well as other oral preventative medications were becoming more widely distributed in nursing homes. Furthermore, follow-up for the residents infected during the omicron period was much shorter than the delta variant cohort, with 414 of 1864 residents in the omicron cohort without the full 28-day follow-up for mortality, which might have biased results to lower mortality reports during the omicron wave.